 we report on our second quarter 2019 financial results and discuss our plans for advancing our 2 lead compounds, 506 and AB-729, through a combination proof-of-concept trial in subjects with chronic hepatitis b in the second half of 2020.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 